LGM Pharma, a provider of tailored API and CDMO services for the full drug product lifecycle, today announced a significant enhancement of its capabilities: a 50% expansion and an investment exceeding $2 million in its standalone offering for Analytical Testing Services. (ATS)
Its also introducing novel suppository manufacturing capabilities to its contract development and manufacturing (CDMO) portfolio.
These strategic enhancements provide additional internal bandwidth for growth while also providing customers greater flexibility with a streamlined, efficient and comprehensive solution for their manufacturing needs.
Standalone analytical testing services
With an array of analytical testing capabilities for small-molecule drug substances and drug products, LGM Pharma can meet the demands of large and small clients, from established pharmaceutical companies to start-ups.
In addition to analytical testing, the company provides method development and validation services, as well as stability testing, including real-time and accelerated stability studies.
LGM Pharma’s analytical laboratories, located at the CDMO’s facility in Irvine, California, are equipped with chromatography and spectroscopy instrumentation, including ICP-MS and ICP-OES.
“Offering standalone analytical testing expands our agility and capacity to serve as a strategic resource for our pharmaceutical partners, providing them with flexibility to meet the precise needs of their expanding product portfolios,” said Prasad Raje, PhD, CEO at LGM Pharma.
Suppository formulation and manufacturing
As demand for suppositories gains significant traction, especially in the realm of women’s health products, LGM Pharma is expanding its manufacturing capacity at its facility in Rosenburg, Texas.
Suppository drug delivery systems enable more direct and efficient drug absorption for precise drug release kinetics, including for high medication concentrations and extended drug release times.
They provide an excellent solution for patients with difficulty swallowing pills or those experiencing nausea, as well as for chronic conditions and women’s health.
“As patient needs become increasingly diversified, the pharmaceutical industry needs CDMO partners that can provide specialised capabilities,” said Ian Gibson, Executive Vice President of Operations at LGM Pharma. “Our expertise in suppository formulation development and manufacturing, including the most advanced delivery systems, represents another example of our dedication to providing strategic solutions to our industry partners.”
